3 Catalysts That Could Make or Break Novo Nordisk

Novo Nordisk scores a 7.0/10 from Motley Fool analysts — strong finances but heavy semaglutide concentration.
We break down the pipeline, legal risks, and what investors should monitor next.
– Why semaglutide concentration (~70% of revenue) is the biggest single-molecule risk
– How CagriSema and Amycretin could diversify growth and affect valuation
– The competitive threat from Eli Lilly and potential FDA action on copycat GLP-1s
– Legal developments, including the Hims and Hers lawsuit, that could reshape market dynamics
– Financial picture: high margins, record cash flow, and a recent $14B debt increase for manufacturing
– Valuation takeaway: Motley Fool sees a reset with possible 10–15% five-year upside if execution succeeds
————————————————————————
This video is brought to you by The Motley Fool.
Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 938% as of 3/18/2026 and measured against the S&P 500 returns of 188% as of 3/18/2026. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
————————————————————————